U.S. Markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.26-0.89 (-4.90%)
At close: 4:00PM EDT

17.26 -0.00 (-0.00%)
After hours: 4:53PM EDT

Full screen
Loading interactive chart...
  • Intercept to Present at the 2021 RBC Capital Markets Global Healthcare Conference
    GlobeNewswire

    Intercept to Present at the 2021 RBC Capital Markets Global Healthcare Conference

    NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 4:50 p.m. ET. A live webcast of the event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An audio archive of the webcast will also be available on Intercept’s website for approximately two weeks. About InterceptIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn. CONTACT For more information about Intercept, please contact: Investor inquiries: investors@interceptpharma.com Media inquiries: media@interceptpharma.com Source: Intercept Pharmaceuticals, Inc.

  • If You Had Bought Intercept Pharmaceuticals' (NASDAQ:ICPT) Shares Five Years Ago You Would Be Down 87%
    Simply Wall St.

    If You Had Bought Intercept Pharmaceuticals' (NASDAQ:ICPT) Shares Five Years Ago You Would Be Down 87%

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...

  • Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat
    Zacks

    Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat

    Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations. However, Ocaliva's safety label remains a concern.